Life-Extending Breast Cancer Drug Enhertu Approved for NHS Use in England Following Campaign

Thousands of breast cancer patients in England have been given fresh hope following the approval of the life-prolonging drug Enhertu for routine use on the National Health Service. The decision marks a major breakthrough for women living with advanced stages of the disease, coming two years after health regulators initially blocked the medication on the grounds of cost.

The targeted therapy is specifically approved for patients diagnosed with HER2-low metastatic breast cancer, an incurable form of the disease that has spread to other areas of the body. Clinical evidence indicates that the drug can offer patients an average of nearly seven additional months of life, with some individuals surviving up to three years longer than they would on standard treatments.

The approval is expected to benefit approximately 1,000 women across England each year. Doctors have been authorized to begin prescribing the treatment immediately. While NHS Scotland has provided the drug to eligible patients since 2023, and 26 other European nations already make it accessible, access in England had been stalled following previous negative assessments.

The regulatory shift in England is expected to influence other parts of the United Kingdom soon. Wales is anticipated to adopt similar guidance in the near future, although the newly issued recommendation does not automatically apply to the healthcare system in Northern Ireland.

Health Secretary Yvette Cooper welcomed the availability of the therapy, describing the drug as potentially life-changing for families facing terminal diagnoses. Cooper emphasized that the recommendation ensures NHS patients will finally receive the medication, paying tribute to the sustained efforts of grassroots campaigners and charitable organizations who spent years demanding broader access.

The approval follows a prolonged funding deadlock between health officials and pharmaceutical manufacturers Daiichi Sankyo and AstraZeneca. The National Institute for Health and Care Excellence (NICE) had previously concluded in 2024 that the medication was not sufficiently cost-effective for state funding, sparking widespread public outcry and political pressure.

Although the drug manufacturers did not substantially reduce their prices from initial negotiations, a series of broader policy adjustments cleared the path for approval. The reversal was heavily influenced by a wider trade agreement with the United States, under which the British government committed to increasing overall expenditure on medicines by 25 percent.

Alongside this agreement, NICE updated its standard economic evaluation methods used to determine whether treatments represent good value for taxpayers. The body raised its upper threshold for a Quality-Adjusted Life Year (QALY)—the metric determining the value of one year of good-quality health—from £30,000 to £35,000, creating greater financial headroom for specialized cancer therapies.

In addition to the revised monetary cap, NICE implemented a more nuanced framework for calculating patient quality of life at the end of August. These combined technical adjustments, coupled with strong advocacy from patient groups, successfully altered the cost-benefit balance in favor of greenlighting Enhertu.

Helen Knight, the director of medicines evaluation at NICE, expressed satisfaction that a viable commercial solution had finally been achieved to enable patients to receive the treatment through the NHS.

Advocacy groups have greeted the news with a mixture of immense relief and profound sorrow for those who did not survive to see the decision. Claire Rowney, the chief executive of Breast Cancer Now, stated that while campaigners could finally celebrate their persistence paying off, the victory remained bittersweet given the lives lost during the lengthy delay.

Rowney urged systemic changes across the healthcare establishment, calling on government ministers, NHS England, NICE, and the pharmaceutical industry to reform drug appraisal mechanisms. She stressed that patients with incurable secondary breast cancer should never have to spend their remaining months campaigning for access to proven treatments.

Among those directly affected by the ruling is Kate Wills, a 51-year-old mother with HER2-low metastatic breast cancer that has spread to her lungs and bones. Wills, who continues to balance a demanding career with family life, described the agonizing reality of knowing a drug existed that could prolong her life while being unable to receive it on the NHS.

Upon learning of the approval, Wills was moved to tears, describing the announcement as an enormous source of hope after years of living under the shadow of a terminal diagnosis. She shared that the availability of Enhertu had transformed her personal outlook for the future.

Previously, Wills had focused her goals on staying alive long enough to watch her youngest child complete secondary education. With access to the new treatment, she noted that she can now allow herself to hope for larger milestones, such as watching her teenage and young adult children fall in love and get married.

However, Wills echoed the sentiment that the decision came too late for many of her peers, including fellow campaigner Jeannie Ambrose. Ambrose had publicly advocated for the drug’s approval two years ago at the age of 53, urging authorities to let patients focus on their families rather than fighting bureaucratic hurdles, before passing away in January.

Addressing the resolution, pharmaceutical companies Daiichi Sankyo and AstraZeneca welcomed NICE's revised recommendation. AstraZeneca highlighted the necessity for closer collaboration among healthcare bodies and manufacturers in the future to ensure treatments reach eligible patients much more quickly and equitably.